James Kaye, MD, DrPH
Adjunct Associate Professor
Boston University School of Public Health
Dept of Epidemiology

MD, Stanford University School of Medicine
DPH/DrPH, Harvard School of Public Health
MPH, Harvard School of Public Health




James Kaye, MD, DrPH, is a medical oncologist/hematologist, epidemiologist, and Senior Director of Epidemiology at RTI-HS. Dr. Kaye completed an internship and residency in internal medicine at the Beth Israel Hospital in Boston and a fellowship in medical oncology/hematology at the Dana Farber Cancer Institute. He then served on the faculty in the Department of Medicine at Harvard Medical School while practicing medical oncology/hematology and coordinating the clinical research program at Harvard Community Health Plan.

In 1991, Dr. Kaye joined the clinical development group at Genetics Institute, Inc. (later Wyeth, now Pfizer) where he directed clinical trials on several hematology/oncology products, two of which were approved for marketing. He participated in numerous Food and Drug Administration interactions, including investigational new drug and biologic license application submissions, advisory committee presentations, and label negotiations.

Dr. Kaye subsequently completed doctoral training in pharmacoepidemiology with a focus on pharmaceuticals and cancer risk. He was senior epidemiologist at the Boston Collaborative Drug Surveillance Program and a faculty member at Boston University School of Public Health, where he continues to serve as adjunct associate professor of epidemiology.

In 2009, Dr. Kaye joined RTI-HS, where he conducts research on postmarketing safety issues (especially cancer risk) and advises RTI-HS staff on a variety of health economics, biostatistics, and other projects relating to hematology/oncology drugs in development. He has chaired or participated in numerous independent data monitoring committees for clinical trials of drugs for the treatment of cancer or hematologic diseases, and he consults with clients on the assessment of cancer-related safety issues for drugs used in other indications. Dr. Kaye has authored more than 100 articles in the peer-reviewed medical literature.

Senior Director, Epidemiology
RTI Health Solutions


Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

  1. Kabadi SM, Goyal RK, Nagar SP, Kaye JA, Davis KL. Treatment patterns, adverse events, and economic burden in a privately insured population of patients with chronic lymphocytic leukemia in the United States. Cancer Med. 2019 May 29. PMID: 31144473.
     
  2. Goyal RK, Cuyun Carter G, Nagar SP, Smyth EN, Price GL, Huang YJ, Li L, Davis KL, Kaye JA. Treatment patterns, survival, and economic outcomes in Medicare-enrolled, older patients with HR+/HER2- metastatic breast cancer. Curr Med Res Opin. 2019 May 07; 1. PMID: 31060392.
     
  3. Vickers AD, Winfree KB, Cuyun Carter G, Kiiskinen U, Jen MH, Stull D, Kaye JA, Carbone DP. Relative efficacy of interventions in the treatment of second-line non-small cell lung cancer: a systematic review and network meta-analysis. BMC Cancer. 2019 Apr 15; 19(1):353. PMID: 30987609.
     
  4. Margulis AV, Fortuny J, Kaye JA, Calingaert B, Reynolds M, Plana E, McQuay LJ, Jan Atsma W, Franks B, de Vogel S, Perez-Gutthann S, Arana A. Proportions of Cancer Cases in Primary Care, Hospital, and Cancer Registry Data Among Patients Treated for Overactive Bladder. Epidemiology. 2019 03; 30(2):e8-e9. PMID: 30489349.
     
  5. Saltus CW, Vassilev ZP, Zong J, Calingaert B, Andrews EB, Soriano-Gabarró M, Kaye JA. Incidence of Second Primary Malignancies in Patients with Castration-Resistant Prostate Cancer: An Observational Retrospective Cohort Study in the United States. Prostate Cancer. 2019; 2019:4387415. PMID: 30886751.
     
  6. Barrows SM, Wright K, Copley-Merriman C, Kaye JA, Chioda M, Wiltshire R, Torgersen KM, Masters ET. Systematic review of sequencing of ALK inhibitors in ALK-positive non-small-cell lung cancer. Lung Cancer (Auckl). 2019; 10:11-20. PMID: 30804692.
     
  7. Lin HM, Davis KL, Kaye JA, Luptakova K, Nagar SP, Mohty M. Real-World Treatment Patterns, Outcomes, and Healthcare Resource Utilization in Relapsed or Refractory Multiple Myeloma: Evidence from a Medical Record Review in France. Adv Hematol. 2019; 2019:4625787. PMID: 30838045.
     
  8. Goyal RK, Nagar SP, Kabadi SM, Kaye JA, Seal B, Mato AR. Adverse events, resource use, and economic burden associated with mantle cell lymphoma: a real-world assessment of privately insured patients in the United States. Leuk Lymphoma. 2019 Apr; 60(4):955-963. PMID: 30277099.
     
  9. Mytelka DS, Nagar SP, D'yachkova Y, La EM, Kaye JA, Candrilli SD, Kasper B, Lopez-Martin JA, Lorenzo M. Health Care Resource Utilization and Costs among Adult Patients with Advanced Soft Tissue Sarcoma: A Retrospective Medical Record Review in the United Kingdom, Spain, Germany, and France. Sarcoma. 2018; 2018:2020591. PMID: 30297977.
     
  10. Margulis AV, Fortuny J, Kaye JA, Calingaert B, Reynolds M, Plana E, McQuay LJ, Atsma WJ, Franks B, de Vogel S, Perez-Gutthann S, Arana A. Value of Free-text Comments for Validating Cancer Cases Using Primary-care Data in the United Kingdom. Epidemiology. 2018 09; 29(5):e41-e42. PMID: 29794511; DOI: 10.1097/EDE.0000000000000856;.
     
Showing 10 of 106 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 106 publications over 23 distinct years, with a maximum of 17 publications in 2018

YearPublications
19861
19963
19971
20004
20012
20023
20036
20047
20054
20064
20072
20082
20094
20104
20111
20123
20133
20147
20158
20162
201711
201817
20197
Contact for Mentoring:


RTI Health Solutions, 307 Waverley Oaks Road, Suite 101
Waltham MA 02452-8413
Google Map


Kaye's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Co-Authors
_
Similar People
_
Same Department